Skip header and navigation

Refine By

56 records – page 1 of 6.

A 45-year experience with surgical treatment of peptic ulcer disease in children.

https://arctichealth.org/en/permalink/ahliterature211771
Source
J Pediatr Surg. 1996 Jun;31(6):750-3
Publication Type
Article
Date
Jun-1996
Author
K. Azarow
P. Kim
B. Shandling
S. Ein
Author Affiliation
Division of General Surgery, Hospital for Sick Children, Toronto, Ontario, Canada.
Source
J Pediatr Surg. 1996 Jun;31(6):750-3
Date
Jun-1996
Language
English
Publication Type
Article
Keywords
Anti-Ulcer Agents - therapeutic use
Chi-Square Distribution
Child
Gastric Outlet Obstruction - etiology - surgery
Gastrointestinal Hemorrhage - etiology - surgery
Histamine H2 Antagonists - therapeutic use
Humans
Intestinal Perforation - etiology - surgery
Ontario
Peptic Ulcer - complications - drug therapy - surgery
Proton Pump Inhibitors
Retrospective Studies
Abstract
Peptic ulcer disease (PUD) requiring surgical treatment has become rare with the availability of modern medical management. A retrospective study of all patients who required operations for PUD between 1949 and 1994 (n = 43) was done. The patients were classified into 3 groups: A (n = 38): pre-histamine-2 (H2) blocker era (1949-1975); B (n = 3): pre-hydrogen-potassium (H-K+) ATPase inhibitor era (1976-1988); C (n = 2): H-K+ ATPase inhibitor era (1989-1994). Data, analyzed using X2 analysis (P .01). Children with PUD can have complications similar to those of adults with PUD. Since the introduction of H2 antagonists, the recognition and treatment of H pylori, and the use of H-K+ ATPase inhibition, the incidence of operations for bleeding and perforation has decreased dramatically. However, the incidence of surgery for obstruction remains the same.
PubMed ID
8783092 View in PubMed
Less detail

Bleeding peptic ulcer - time trends in incidence, treatment and mortality in Sweden.

https://arctichealth.org/en/permalink/ahliterature98994
Source
Aliment Pharmacol Ther. 2009 Aug 15;30(4):392-8
Publication Type
Article
Date
Aug-15-2009
Author
J. Sadic
A. Borgström
J. Manjer
E. Toth
G. Lindell
Author Affiliation
Department of Surgery, Malmö University Hospital, Lund University, Malmö, Sweden.
Source
Aliment Pharmacol Ther. 2009 Aug 15;30(4):392-8
Date
Aug-15-2009
Language
English
Publication Type
Article
Keywords
Adult
Age Distribution
Aged
Aged, 80 and over
Anti-Ulcer Agents - therapeutic use
Cohort Studies
Female
Helicobacter Infections - complications - drug therapy
Helicobacter pylori - isolation & purification
Humans
Incidence
Male
Middle Aged
Peptic Ulcer - epidemiology - mortality - therapy
Peptic Ulcer Hemorrhage - epidemiology - mortality - therapy
Risk factors
Sex Distribution
Sweden - epidemiology
Time Factors
Treatment Outcome
Abstract
BACKGROUND: The incidence of peptic ulcer disease was expected to decrease following the introduction of acid inhibitors and Helicobacter pylori eradication. AIM: To analyse possible changes in the incidence of bleeding peptic ulcer, treatment and mortality over time. METHODS: Residents of Malmö hospitalized for bleeding gastric or duodenal ulcer disease during 1987-2004 were identified in hospital databases (n = 1610). The material was divided into 6-year periods to identify changes over time. All patients who had been submitted to emergency surgery (n = 137) were reviewed. RESULTS: The incidence rate for bleeding gastric or duodenal ulcers decreased by one half in males and by one-third in females and emergency operations decreased significantly (9.2%, 7.5% and 5.7% during the three time periods, respectively (P
PubMed ID
19508403 View in PubMed
Less detail

Campylobacter pylori and gastroduodenal ulcer disease. A prospective study in a Swedish population.

https://arctichealth.org/en/permalink/ahliterature231783
Source
Scand J Gastroenterol Suppl. 1989;167:81-5
Publication Type
Article
Date
1989
Author
A. Gad
M. Hradsky
K. Furugård
B. Malmodin
Author Affiliation
Dept. of Clinical Pathology and Cytology, Falun Hospital, Sweden.
Source
Scand J Gastroenterol Suppl. 1989;167:81-5
Date
1989
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Aluminum Hydroxide - therapeutic use
Anti-Ulcer Agents - therapeutic use
Bismuth - therapeutic use
Campylobacter Infections - epidemiology
Drug Combinations - therapeutic use
Female
Glycyrrhiza
Histamine H2 Antagonists - therapeutic use
Humans
Magnesium Hydroxide
Male
Middle Aged
Peptic Ulcer - drug therapy - epidemiology - etiology
Pilot Projects
Plant Extracts - therapeutic use
Prospective Studies
Sodium Bicarbonate
Sweden - epidemiology
Abstract
In a consecutive prospective series of 208 Swedish primary peptic ulcer patients, 146 gastric, 55 duodenal and 7 in both sites, gastroduodenitis was found in 97.6% of the cases. The mucosal inflammation was associated with CP in 87% and 91% of the gastric and duodenal ulcer cases respectively. No significant correlation was found between CP colonisation and the type or severity of mucosal inflammation. Gastric metaplasia was present in only 8% of 48 bulbar ulcer cases. Ulcer healing and eradication of CP was achieved in 52% of patients treated with bismuth subnitrate in combination with erythromycin or according to the triple approach.
PubMed ID
2575789 View in PubMed
Less detail

Campylobacter pylori and non-ulcer dyspepsia. 2. A prospective study in a Swedish population.

https://arctichealth.org/en/permalink/ahliterature231734
Source
Scand J Gastroenterol Suppl. 1989;167:44-8
Publication Type
Article
Date
1989
Author
A. Gad
M. Hradsky
K. Furugård
B. Malmodin
O. Nyberg
Author Affiliation
Dept. of Clinical Pathology and Cytology, Falun Hospital, Sweden.
Source
Scand J Gastroenterol Suppl. 1989;167:44-8
Date
1989
Language
English
Publication Type
Article
Keywords
Adult
Aluminum Hydroxide - therapeutic use
Anti-Ulcer Agents - therapeutic use
Bismuth - therapeutic use
Campylobacter - isolation & purification
Campylobacter Infections - drug therapy - epidemiology
Drug Combinations - therapeutic use
Dyspepsia - drug therapy - epidemiology - etiology
Erythromycin - therapeutic use
Female
Glycyrrhiza
Humans
Magnesium Hydroxide
Male
Plant Extracts - therapeutic use
Prevalence
Prospective Studies
Sodium Bicarbonate
Sweden - epidemiology
Abstract
In a consecutive prospective series of 186 Swedish persons with the diagnosis of non-ulcer dyspepsia 71.5% were found to have gastritis and/or bulbar duodenitis in endoscopic biopsies. Gastroduodenitis was associated with campylobacter pylori (CP) in 83.5% of the cases. The double therapeutic approach using an antibiotic and a preparation containing bismuth in an uncontrolled therapeutic pilot trial resulted in improvement of the histological picture, disappearance of CP and amelioration of symptoms. It is concluded that CP-infection plays a central role in the pathogenesis of gastroduodenitis associated NUD.
PubMed ID
2617168 View in PubMed
Less detail

[Choice of the method of treatment of uncomplicated gastric and duodenal ulcers].

https://arctichealth.org/en/permalink/ahliterature193515
Source
Khirurgiia (Mosk). 2001;(7):13-6
Publication Type
Article
Date
2001
Author
V P Petrov
Source
Khirurgiia (Mosk). 2001;(7):13-6
Date
2001
Language
Russian
Publication Type
Article
Keywords
Adolescent
Adult
Anti-Ulcer Agents - therapeutic use
Child
Child, Preschool
Duodenal Ulcer - drug therapy - epidemiology - surgery
Emergencies
Female
Humans
Infant
Infant, Newborn
Male
Prevalence
Russia - epidemiology
Stomach Ulcer - drug therapy - epidemiology - surgery
Abstract
Three features of ulcer prevalence in Russia and therapeutic policy in ulcer consist of an increase of ulcerous patients number, a decrease of elective operations number for uncomplicated ulcers and an increase of emergency operations rate in complicate ulcer. Decrease of elective operations number leads to increase of emergency operations rate in complicated ulcer. The majority of complicated ulcers has long-term anamnesis, complications develop in chronic ulcers. Expansion of indications to elective operations in uncomplicated gastric and duodenal ulcer is advocated.
PubMed ID
11521301 View in PubMed
Less detail

Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002.

https://arctichealth.org/en/permalink/ahliterature89286
Source
BMC Gastroenterol. 2009;9:25
Publication Type
Article
Date
2009
Author
Hermansson Michael
Ekedahl Anders
Ranstam Jonas
Zilling Thomas
Author Affiliation
Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. michael.hermansson@vgregion.se
Source
BMC Gastroenterol. 2009;9:25
Date
2009
Language
English
Publication Type
Article
Keywords
Aged
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Anti-Ulcer Agents - therapeutic use
Aspirin - adverse effects
Dose-Response Relationship, Drug
Female
Gastrointestinal Hemorrhage - chemically induced - epidemiology - etiology
Helicobacter Infections - complications
Humans
Incidence
Male
Middle Aged
Peptic Ulcer - complications - drug therapy
Peptic Ulcer Perforation - chemically induced - epidemiology - etiology
Proton Pump Inhibitors - therapeutic use
Retrospective Studies
Smoking - adverse effects
Sweden - epidemiology
Abstract
BACKGROUND: Despite a decreasing incidence of peptic ulcer disease, most previous studies report a stabile incidence of ulcer complications. We wanted to investigate the incidence of peptic ulcer complications in Sweden before and after the introduction of the proton pump inhibitors (PPI) in 1988 and compare these data to the sales of non-steroid anti-inflammatory drugs (NSAID) and acetylsalicylic acid (ASA). METHODS: All cases of gastric and duodenal ulcer complications diagnosed in Sweden from 1974 to 2002 were identified using the National hospital discharge register. Information on sales of ASA/NSAID was obtained from the National prescription survey. RESULTS: When comparing the time-periods before and after 1988 we found a significantly lower incidence of peptic ulcer complications during the later period for both sexes (p
PubMed ID
19379513 View in PubMed
Less detail

Determinants of initiation and suboptimal use of anti-ulcer medication: a study of the Quebec older population.

https://arctichealth.org/en/permalink/ahliterature208100
Source
J Am Geriatr Soc. 1997 Jul;45(7):853-6
Publication Type
Article
Date
Jul-1997
Author
Y. Moride
D. Melnychuk
J. Monette
L. Abenhaim
Author Affiliation
Centre for Clinical Epidemiology and Community Studies, McGill University S.M.B.D. Jewish General Hospital, Montreal, Quebec, Canada.
Source
J Am Geriatr Soc. 1997 Jul;45(7):853-6
Date
Jul-1997
Language
English
Publication Type
Article
Keywords
Age Factors
Aged
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Anti-Ulcer Agents - therapeutic use
Cohort Studies
Drug Utilization
Humans
Quebec
Retrospective Studies
Abstract
To describe the use of anti-ulcer medication in the Quebec older population; to examine determinants of initiation, suboptimal use, and switches between products.
Population-based retrospective cohort study.
Universal health program for older adults in Quebec.
5000 users and 5000 non-users of anti-ulcer medications were selected randomly. Use was defined as the presence in the 1991 prescription database of an anti-ulcer prescription. Among users, 1697 (34%) were new users and were considered as the exposure group. Subjects were followed for 365 days after inclusion.
Measured were patient's age, gender, prescribed duration of anti-ulcer medication, concomitant medications, and gastrointestinal diagnostic procedures.
A total of 17% of new users had unusually short courses; 18% were long-term users. There was no difference in duration for omeprazole compared with other anti-ulcer medications. First-time use of NSAIDs was the strongest predictor of initiation of anti-ulcer medication (odds ratio = 3.21; 95% CI, 2.66-3.88). Twenty-six percent of users switched brands. Only 9.5% of new users underwent a diagnostic procedure before initiation of therapy, and 49% of long-term users ever underwent such procedure.
Despite a relatively homogeneous recommended duration of therapy, patterns of use of anti-ulcer medication among older people are highly variable, and treatment is often not accompanied by a diagnostic procedure.
PubMed ID
9215338 View in PubMed
Less detail

Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada.

https://arctichealth.org/en/permalink/ahliterature114964
Source
Pharmacoepidemiol Drug Saf. 2013 Jul;22(7):735-43
Publication Type
Article
Date
Jul-2013
Author
Susan E Tett
Ingrid Sketris
Charmaine Cooke
Sander Veldhuyzen van Zanten
Nadia Barozzi
Author Affiliation
School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.
Source
Pharmacoepidemiol Drug Saf. 2013 Jul;22(7):735-43
Date
Jul-2013
Language
English
Publication Type
Article
Keywords
Age Factors
Anti-Ulcer Agents - therapeutic use
Australia
Chi-Square Distribution
Data Mining
Databases, Factual - statistics & numerical data
Drug Prescriptions - statistics & numerical data
Drug Utilization Review - trends
Histamine H2 Antagonists - therapeutic use
Humans
Nova Scotia
Pharmacoepidemiology
Pharmacovigilance
Physician's Practice Patterns - trends
Proton Pump Inhibitors - therapeutic use
Social Security
Time Factors
Abstract
This study aimed to compare use of histamine H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs), 2001-2005, in the elderly and social security beneficiaries in Australia (AUS) and Nova Scotia, Canada (NS).
Prescription dispensing data were collected for all subsidised H2RAs and PPIs. In AUS, dispensing data for concession beneficiaries were obtained from the Pharmaceutical Benefits Scheme database. In NS, data were sourced from the Pharmacare database. Relevant population data were used to convert to World Health Organisation Anatomic Therapeutic Chemical defined daily doses (2005) per 1000 beneficiaries per day (DDD/1000/day).
Overall use of gastroprotective agents was similar and rising in NS and AUS (100-160?DDD/1000/day) over this 5-year time window. However, the proportion of this use accounted for by PPIs was far higher in AUS (over 85% by 2005) than in NS (23% rising to 35% over the 5?years). In AUS, PPI use rose from 50 to about 140?DDD/1000/day over the 5?years, whereas PPI use in NS rose slowly to less than 60?DDD/1000/day by 2005. H2RA use in NS was always high (over 100?DDD/1000/day), whereas in AUS, H2RA use fell from 54 to around 24?DDD/1000/day over this period.
AUS had much higher use of PPIs than NS over 2001-2005. The proportion of PPIs in all gastroprotective agents rose in AUS to be nearly 90%. The differences in utilisation during this time window could lead to differences in health outcomes from either lower gastro-intestinal bleeding risk or higher long-term adverse effects of PPIs.
PubMed ID
23559528 View in PubMed
Less detail

56 records – page 1 of 6.